Walleye Capital’s Aptose Biosciences, Inc. APTO Stock Holding History

Walleye Capital’s Portfolio APTO Stock Details APTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-159	Closed	-$96K	–	2747
2021 Q4	$96K	Sell	159 -471	-75%	-$443K	﹤0.01%	1696
2021 Q3	$618K	Buy	+630	New	+$788K	0.02%	691
2020 Q1	–	Sell	-70	Closed	-$180K	–	1873
2019 Q4	$180K	Buy	+70	New	+$91.2K	0.01%	1157

Other funds holding APTO

DRW Securities Chicago, Illinois $4.11B AUM 21.98% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $755M AUM 11.28% 1-Year Est. Return

Carlson Capital Dallas, Texas $494M AUM 23.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sigma Planning Corp Ann Arbor, Michigan $3.97B AUM 32.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Walleye Capital's APTO Position: Q1 2022 in Review

Walleye Capital sold out of Aptose Biosciences, Inc. (APTO) in Q1 2022, closing a stake of 159 shares — an estimated $96K sold.

Walleye Capital first reported a position in APTO in Q4 2019 and held it in 3 quarters. The position peaked at $618K in Q3 2021. 52 funds tracked by Wall St. Rank hold APTO as of Q1 2022.

Walleye Capital reported no remaining Aptose Biosciences, Inc. position as of Q1 2022 after selling out during the quarter.
Walleye Capital sold 159 Aptose Biosciences, Inc. shares in Q1 2022, an estimated $96K.
Walleye Capital first reported a position in Aptose Biosciences, Inc. in Q4 2019 and held it in 3 quarters.
Walleye Capital's Aptose Biosciences, Inc. position peaked at $618K in Q3 2021.
52 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q1 2022.

Based on Walleye Capital's 13F filing for Q1 2022, filed 16 May 2022.